Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Sterility After Ethyl-Chloride Spray

NCT01292850
View directory record Official record
Conditions
Skin Sterility After Use of Ethyl-chloride Spray.
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042
View directory record Official record
Conditions
Healthy
Interventions
Within-Subject Active vs. Placebo Topical Applications
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Topical Lidocaine Decrease Sweat During Exercise in the Heat?

NCT05379283
View directory record Official record
Conditions
Sweat Pore Closure
Interventions
Lidocaine, control
Drug · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

NCT02930941
View directory record Official record
Conditions
Epistaxis
Interventions
Tranexamic Acid, 0.9% Sodium Chloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm

NCT05082376
View directory record Official record
Conditions
Sunscreening Agents
Interventions
CLM Original
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 20, 2026, 11:10 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

NCT03094468
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
P-3058 (terbinafine hydrochloride 10%), Vehicle of P-3058
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
North Hollywood, California • Oceanside, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

PEMF: an Adjunct Therapy for Anterior Uveitis

NCT01154010
View directory record Official record
Conditions
Anterior Uveitis, Iritis
Interventions
PEMF, PEMF Placebo
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film

NCT04731818
View directory record Official record
Conditions
Contraception
Interventions
ZB-06
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

NCT03487588
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Topical Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Fort Washington, Pennsylvania • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

NCT03321513
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

NCT02062060
View directory record Official record
Conditions
Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/w, Vehicle Lotion
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
6 Months and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Yuma, Arizona • Los Angeles, California • Pinellas Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

NCT06366503
View directory record Official record
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Blue Ash, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756
View directory record Official record
Conditions
Solid Tumor, Hand-Foot Skin Reaction (HFSR)
Interventions
Topical Tazarotene, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 11:10 PM EDT